The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
Modulating Glycolysis to Improve Cancer Therapy
Open accessAbstract
Cancer cells undergo metabolic reprogramming and switch to a ‘glycolysis-dominant’ metabolic profile to promote their survival and meet their requirements for energy and macromolecules. This phenomenon, also known as the ‘Warburg effect,’ provides a survival advantage to the cancer cells and make the tumor environment more pro-cancerous. Additionally, the increased glycolytic dependence also promotes chemo/radio resistance. A similar switch to a glycolytic metabolic profile is also shown by the immune cells in the tumor microenvironment, inducing a competition between the cancer cells and the tumor-infiltrating cells over nutrients. Several recent studies have shown that targeting the enhanced glycolysis in cancer cells is a promising strategy to make them more susceptible to treatment with other conventional treatment modalities, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, and photodynamic therapy. Although several targeting strategies have been developed and several of them are in different stages of pre-clinical and clinical evaluation, there is still a lack of effective strategies to specifically target cancer cell glycolysis to improve treatment efficacy. Herein, we have reviewed our current understanding of the role of metabolic reprogramming in cancer cells and how targeting this phenomenon could be a potential strategy to improve the efficacy of conventional cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
He, T., Zhang, Y.-J., Jiang, H., Li, X.-H., Zhu, H., & Zheng, K.-L. (2015) · Medical Oncology · doi:10.1007/s12032-015-0633-8 · Cited by 130
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“Several studies have reported that the metabolic reprogramming of the cancer cell that leads to the development of an immunosuppressive tumor microenvironment is one of the main contributors to the reduced efficacy of immunotherapy [163].”
BackgroundTop 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 5×
“The LKB1-dependent kinases regulate metabolic pathways by targeting several effectors, including AMPK [197].”
BackgroundInfluentialMetabolic reprogramming in macrophages and dendritic cells in innate immunity
Kelly, B., & O'Neill, L. A. (2015) · Cell Research · doi:10.1038/cr.2015.68 · Cited by 1,876
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559
Role of PFKFB3-Driven Glycolysis in Vessel Sprouting
De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B. W., Cantelmo, A. R., Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.037 · Cited by 1,551
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
The Science and Translation of Lactate Shuttle Theory
Brooks, G. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.008 · Cited by 1,486
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169 · cited 1×
“It was also shown that blocking glutamine metabolism increases T-cell function [217].”
BackgroundActivating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,115
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology
Kierans, S. J., & Taylor, C. T. (2021) · The Journal of Physiology · doi:10.1113/jp280572 · Cited by 1,015
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952 · cited 1×
“Inhibiting glycolysis using the HK-2 inhibitor, 2-DG, before ACT induced a memory-like phenotype in the T-cells, enabling a more efficient control of tumors and prolonged survival in an animal model [219].”
MethodChromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Lu, Z. (2012) · Nature Cell Biology · doi:10.1038/ncb2629 · Cited by 918
Scharping, N. E., Rivadeneira, D. B., Menk, A. V., Vignali, P. D. A., Ford, B. R., Rittenhouse, N. L., Peralta, R., Wang, Y., Wang, Y., DePeaux, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00834-9 · Cited by 897
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
Jacobs, S. R., Herman, C. E., MacIver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., & Rathmell, J. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4476 · Cited by 850
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Reck, M., Remon, J., & Hellmann, M. D. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01497 · Cited by 842
Mitochondrial Metabolism as a Target for Cancer Therapy
Vasan, K., Werner, M., & Chandel, N. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.019 · Cited by 736
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
Gerriets, V. A., Kishton, R. J., Nichols, A. G., Macintyre, A. N., Inoue, M., Ilkayeva, O., Winter, P. S., Liu, X., Priyadharshini, B., Slawinska, M. E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76012 · Cited by 731
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Tumor Mitochondria and the Bioenergetics of Cancer Cells
Pedersen, P. L. (2015) · Progress in Tumor Research · doi:10.1159/000401202 · Cited by 711
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Cantelmo, A. R., Conradi, L.-C., Brajic, A., Goveia, J., Kalucka, J., Pircher, A., Chaturvedi, P., Hol, J., Thienpont, B., Teuwen, L.-A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.006 · Cited by 659
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.010 · Cited by 656 · cited 1×
“mTOR kinases determine effector and memory CD8+ T-cell fates, and blocking mTOR promotes T-cell effector functions [205,206].”
BackgroundCalcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., Williams, L. J., Wang, Z., Bristow, C. A., Carugo, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.024 · Cited by 611
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00541-y · Cited by 597
Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion
Yu, Y.-R., Imrichova, H., Wang, H., Chao, T., Xiao, Z., Gao, M., Rincon-Restrepo, M., Franco, F., Genolet, R., Cheng, W.-C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0793-3 · Cited by 593
Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014769108 · Cited by 586
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560 · cited 1×
“Although hypoxia-inducible factor-1α (HIF1α), expressed in response to hypoxia, can induce Tregs and bind to the promoter region of the FOXP3 to promote transcription [191] (22988108), it contributes to the development of an immunosuppressive TME by enhancing cancer-promoting immune cell functions [192,193].”
BackgroundMetabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression
Gerriets, V. A., Kishton, R. J., Johnson, M. O., Cohen, S., Siska, P. J., Nichols, A. G., Warmoes, M. O., de Cubas, A. A., MacIver, N. J., Locasale, J. W., et al. (2016) · Nature Immunology · doi:10.1038/ni.3577 · Cited by 539
Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis
Schoors, S., De Bock, K., Cantelmo, A. R., Georgiadou, M., Ghesquière, B., Cauwenberghs, S., Kuchnio, A., Wong, B. W., Quaegebeur, A., Goveia, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.008 · Cited by 529
Xie, H., Hanai, J.-I., Ren, J.-G., Kats, L., Burgess, K., Bhargava, P., Signoretti, S., Billiard, J., Duffy, K. J., Grant, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.003 · Cited by 516
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Li, W., Tanikawa, T., Kryczek, I., Xia, H., Li, G., Wu, K., Wei, S., Zhao, L., Vatan, L., Wen, B., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.022 · Cited by 446
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Bohn, T., Rapp, S., Luther, N., Klein, M., Bruehl, T.-J., Kojima, N., Aranda Lopez, P., Hahlbrock, J., Muth, S., Endo, S., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0226-8 · Cited by 436
Pedersen, P. L. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9094-x · Cited by 425
Role of Endothelial Cell Metabolism in Vessel Sprouting
De Bock, K., Georgiadou, M., & Carmeliet, P. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.001 · Cited by 423
Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα
Guo, D., Tong, Y., Jiang, X., Meng, Y., Jiang, H., Du, L., Wu, Q., Li, S., Luo, S., Li, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.002 · Cited by 423
Oncometabolites: linking altered metabolism with cancer
Yang, M., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 422
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
Siska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α
Handschin, C., Lin, J., Rhee, J., Peyer, A.-K., Chin, S., Wu, P.-H., Meyer, U. A., & Spiegelman, B. M. (2005) · Cell · doi:10.1016/j.cell.2005.06.040 · Cited by 383
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 373
Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity
Xu, K., Yin, N., Peng, M., Stamatiades, E. G., Shyu, A., Li, P., Zhang, X., Do, M. H., Wang, Z., Capistrano, K. J., et al. (2021) · Science · doi:10.1126/science.abb2683 · Cited by 364
Pedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., & Ko, Y. H. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(02)00248-7 · Cited by 356
The multiple roles of LDH in cancer
Claps, G., Faouzi, S., Quidville, V., Chehade, F., Shen, S., Vagner, S., & Robert, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00686-2 · Cited by 351
Zeng, H., Cohen, S., Guy, C., Shrestha, S., Neale, G., Brown, S. A., Cloer, C., Kishton, R. J., Gao, X., Youngblood, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.017 · Cited by 345
Pacella, I., Procaccini, C., Focaccetti, C., Miacci, S., Timperi, E., Faicchia, D., Severa, M., Rizzo, F., Coccia, E. M., Bonacina, F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720113115 · Cited by 344
Miyamoto, S., Murphy, A. N., & Brown, J. H. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402285 · Cited by 339
PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation
Azoitei, N., Becher, A., Steinestel, K., Rouhi, A., Diepold, K., Genze, F., Simmet, T., & Seufferlein, T. (2016) · Molecular Cancer · doi:10.1186/s12943-015-0490-2 · Cited by 336
Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship
Netea-Maier, R. T., Smit, J. W. A., & Netea, M. G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.037 · Cited by 326
Exosome-mediated breast cancer chemoresistance via miR-155 transfer
Santos, J. C., Lima, N. D. S., Sarian, L. O., Matheu, A., Ribeiro, M. L., & Derchain, S. F. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19339-5 · Cited by 325
Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1043026 · Cited by 323
Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation
Mendler, A. N., Hu, B., Prinz, P. U., Kreutz, M., Gottfried, E., & Noessner, E. (2012) · International Journal of Cancer · doi:10.1002/ijc.26410 · Cited by 319
Photodynamic Therapy for Cancer: What's Past is Prologue
Hamblin, M. R. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13190 · Cited by 310
Wang, L., Liu, Y., Dai, Y., Tang, X., Yin, T., Wang, C., Wang, T., Dong, L., Shi, M., Qin, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-326070 · Cited by 306
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
Zhao, Y., Liu, H., Liu, Z., Ding, Y., LeDoux, S. P., Wilson, G. L., Voellmy, R., Lin, Y., Lin, W., Nahta, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0127 · Cited by 289
Fu, Q.-F., Liu, Y., Fan, Y., Hua, S.-N., Qu, H.-Y., Dong, S.-W., Li, R.-L., Zhao, M.-Y., Zhen, Y., Yu, X.-L., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0117-5 · Cited by 286
Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway
Shime, H., Yabu, M., Akazawa, T., Kodama, K., Matsumoto, M., Seya, T., & Inoue, N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7175 · Cited by 285
Reeves, G. K., Beral, V., Green, J., Gathani, T., & Bull, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70911-1 · Cited by 284
Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis
Jin, L., Chun, J., Pan, C., Alesi, G. N., Li, D., Magliocca, K. R., Kang, Y., Chen, Z. G., Shin, D. M., Khuri, F. R., et al. (2017) · Oncogene · doi:10.1038/onc.2017.6 · Cited by 281
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
Boudreau, A., Purkey, H. E., Hitz, A., Robarge, K., Peterson, D., Labadie, S., Kwong, M., Hong, R., Gao, M., Del Nagro, C., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2143 · Cited by 280
Yang, X., Lu, Y., Hang, J., Zhang, J., Zhang, T., Huo, Y., Liu, J., Lai, S., Luo, D., Wang, L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0111 · Cited by 277
Kopf, H., de la Rosa, G. M., Howard, O. M. Z., & Chen, X. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.08.027 · Cited by 270
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266 · cited 1×
“Owing to their inhibitory effects, several rapamycin analogs have been approved for treating cancers [231,232].”
BackgroundŽdralević, M., Brand, A., Di Ianni, L., Dettmer, K., Reinders, J., Singer, K., Peter, K., Schnell, A., Bruss, C., Decking, S.-M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004180 · Cited by 255
Efstathiou, E., Titus, M., Wen, S., Hoang, A., Karlou, M., Ashe, R., Tu, S. M., Aparicio, A., Troncoso, P., Mohler, J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.05.005 · Cited by 248
Extracellular ATP: A Feasible Target for Cancer Therapy
Vultaggio-Poma, V., Sarti, A. C., & Di Virgilio, F. (2020) · Cells · doi:10.3390/cells9112496 · Cited by 248
The liver kinase B1 is a central regulator of T cell development, activation, and metabolism
MacIver, N. J., Blagih, J., Saucillo, D. C., Tonelli, L., Griss, T., Rathmell, J. C., & Jones, R. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100367 · Cited by 235
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker
Carvalho, K. C., Cunha, I. W., Rocha, R. M., Ayala, F. R., Cajaíba, M. M., Begnami, M. D., Vilela, R. S., Paiva, G. R., Andrade, R. G., & Soares, F. A. (2011) · Clinics · doi:10.1590/s1807-59322011000600008 · Cited by 229
Klebanoff, C. A., Crompton, J. G., Leonardi, A. J., Yamamoto, T. N., Chandran, S. S., Eil, R. L., Sukumar, M., Vodnala, S. K., Hu, J., Ji, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95103 · Cited by 228
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
Pusapati, R. V., Daemen, A., Wilson, C., Sandoval, W., Gao, M., Haley, B., Baudy, A. R., Hatzivassiliou, G., Evangelista, M., & Settleman, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.018 · Cited by 222
Song, Y., Luo, Q., Long, H., Hu, Z., Que, T., Zhang, X., Li, Z., Wang, G., Yi, L., Liu, Z., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-65 · Cited by 220
Therapeutic strategies targeting cancer stem cells
Yoshida, G. J., & Saya, H. (2016) · Cancer Science · doi:10.1111/cas.12817 · Cited by 214
Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming
Chae, Y. C., Vaira, V., Caino, M. C., Tang, H.-Y., Seo, J. H., Kossenkov, A. V., Ottobrini, L., Martelli, C., Lucignani, G., Bertolini, I., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.004 · Cited by 209
Huang, C. K., Sun, Y., Lv, L., & Ping, Y. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2021.12.026 · Cited by 206
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200
Glucose Transporters as a Target for Anticancer Therapy
Pliszka, M., & Szablewski, L. (2021) · Cancers · doi:10.3390/cancers13164184 · Cited by 199
Chapman, N. M., Zeng, H., Nguyen, T.-L. M., Wang, Y., Vogel, P., Dhungana, Y., Liu, X., Neale, G., Locasale, J. W., & Chi, H. (2018) · Nature Communications · doi:10.1038/s41467-018-04392-5 · Cited by 192
Guedan, S., Madar, A., Casado-Medrano, V., Shaw, C., Wing, A., Liu, F., Young, R. M., June, C. H., & Posey, A. D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133215 · Cited by 189
Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., & Kitanaka, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2892 · Cited by 188
Zhao, Z., Han, F., Yang, S., Wu, J., & Zhan, W. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.046 · Cited by 181
Hsu, M.-C., & Hung, W.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0791-3 · Cited by 179
Cassim, S., Vučetić, M., Ždralević, M., & Pouyssegur, J. (2020) · Cancers · doi:10.3390/cancers12051119 · Cited by 175
Palsson-McDermott, E. M., Dyck, L., Zasłona, Z., Menon, D., McGettrick, A. F., Mills, K. H. G., & O’Neill, L. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01300 · Cited by 173
Pouysségur, J., Marchiq, I., Parks, S. K., Durivault, J., Ždralević, M., & Vucetic, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.004 · Cited by 172
Fan, T., Sun, G., Sun, X., Zhao, L., Zhong, R., & Peng, Y. (2019) · Cancers · doi:10.3390/cancers11030317 · Cited by 171
Chen, D.-P., Ning, W.-R., Jiang, Z.-Z., Peng, Z.-P., Zhu, L.-Y., Zhuang, S.-M., Kuang, D.-M., Zheng, L., & Wu, Y. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.007 · Cited by 170
Sun, H., Wang, H., Wang, X., Aoki, Y., Wang, X., Wang, Z., Cheng, X., Wang, Z., & Wang, X. (2020) · Theranostics · doi:10.7150/thno.43811 · Cited by 169
The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis
Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17445 · Cited by 166
Synergistic Anti-Cancer Effect of Phenformin and Oxamate
Miskimins, W. K., Ahn, H. J., Kim, J. Y., Ryu, S., Jung, Y., & Choi, J. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085576 · Cited by 165
Gemta, L. F., Siska, P. J., Nelson, M. E., Gao, X., Liu, X., Locasale, J. W., Yagita∥, H., Slingluff, C. L., Hoehn, K. L., Rathmell, J. C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aap9520 · Cited by 165
Glucose Metabolism and Glucose Transporters in Breast Cancer
Shin, E., & Koo, J. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728759 · Cited by 164
Siska, P. J., van der Windt, G. J. W., Kishton, R. J., Cohen, S., Eisner, W., MacIver, N. J., Kater, A. P., Weinberg, J. B., & Rathmell, J. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502464 · Cited by 163
Glyoxalase in tumourigenesis and multidrug resistance
Thornalley, P. J., & Rabbani, N. (2011) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2011.02.006 · Cited by 162
Principe, M., Borgoni, S., Cascione, M., Chattaragada, M. S., Borgogno, S. F., Capello, M., Bulfamante, S., Chapelle, J., Modugno, F. D., Defilippi, P., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0385-8 · Cited by 162
Clinical development of metabolic inhibitors for oncology
Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R., & Slusher, B. S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148550 · Cited by 162
Capello, M., Borgogno, S. F., Riganti, C., Chattaragada, M. S., Principe, M., Roux, C., Zhou, W., Petricoin, E. F., Cappello, P., & Novelli, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6798 · Cited by 160
Mondal, S., Roy, D., Bhattacharya, S. S., Jin, L., Jung, D., Zhang, S., Kalogera, E., Staub, J. K., Wang, Y., Xuyang, W., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31868 · Cited by 156
The Complex Integration of T-cell Metabolism and Immunotherapy
Madden, M. Z., & Rathmell, J. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0569 · Cited by 156
Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated Tumorigenesis
Zha, X., Wang, F., Wang, Y., He, S., Jing, Y., Wu, X., & Zhang, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1668 · Cited by 152
Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy
Geltink, R. I. K., Edwards-Hicks, J., Apostolova, P., O’Sullivan, D., Sanin, D. E., Patterson, A. E., Puleston, D. J., Ligthart, N. A. M., Buescher, J. M., Grzes, K. M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0256-z · Cited by 152
Pértega‐Gomes, N., Felisbino, S. L., Massie, C. E., Vizcaino, J. R., Coelho, R., Sandi, C., Simoes‐Sousa, S., Jurmeister, S., Ramos‐Montoya, A., Asim, M., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4547 · Cited by 149
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Mahammedi, H., Planchat, E., Pouget, M., Durando, X., Curé, H., Guy, L., Van-Praagh, I., Savareux, L., Atger, M., Bayet‐Robert, M., et al. (2016) · Oncology · doi:10.1159/000441148 · Cited by 144
Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer
Qian, X., Xu, W., Xu, J., Shi, Q., Li, J., Weng, Y., Jiang, Z., Feng, L., Wang, X., Zhou, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17868 · Cited by 143
Kobuchi, H., Moriya, K., Ogino, T., Fujita, H., Inoue, K., Shuin, T., Yasuda, T., Utsumi, K., & Utsumi, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050082 · Cited by 137
3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy
Ganapathy‐Kanniappan, S., Vali, M., Kunjithapatham, R., Buijs, M., Syed, L. H., Rao, P. P., Ota, S., Kwak, B. K., Loffroy, R., & Geschwind, J. F. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110791591427 · Cited by 137
Tu, S., Chang, C.-C., Chen, C.-S., Tam, K., Wang, Y., Lee, C., Lin, H. W., Cheng, T., Huang, C.-S., Chu, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0492-0 · Cited by 135
Woo, Y. M., Shin, Y., Lee, E. J., Lee, S., Jeong, S. H., Kong, H. K., Park, E. Y., Kim, H. K., Han, J., Chang, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132285 · Cited by 134
Self-citationPhenformin as an Anticancer Agent: Challenges and Prospects
Rubiño, M. E. G., Carrillo, E., Ruiz-Alcalá, G., Domínguez‐Martín, A., Marchal, J. A., & Boulaiz, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133316 · Cited by 133
Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Kohnken, R. A., Kodigepalli, K. M., & Wu, L. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0446-6 · Cited by 130
Zhu, W. J., Liang, Y. S., Zhang, J., Yu, P., Wang, H., Ye, Z., & Tian, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163768 · Cited by 125
Crosstalk between Estrogen Signaling and Breast Cancer Metabolism
Kulkoyluoglu‐Cotul, E., Blanco, A. A., & Madak‐Erdogan, Z. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.10.006 · Cited by 125
Ford, B. R., Vignali, P., Rittenhouse, N., Scharping, N. E., Peralta, R. M., Lontos, K., Frisch, A. T., Delgoffe, G. M., & Poholek, A. C. (2022) · Science Immunology · doi:10.1126/sciimmunol.abj9123 · Cited by 125
Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy
Cerezo, M., & Rocchi, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03175-5 · Cited by 124
Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.
Zhang, X. D., Deslandes, E., Villedieu, M., Poulain, L., Duval, M., Gauduchon, P., Schwartz, L. H., & Icard, P. (2006) · PubMed · Cited by 123
Tsai, S., Chien, I.-H., Shen, W.-H., Kuo, Y.-Z., Jin, Y., Wong, T., Hsiao, J., Wang, H.-P., Shih, N., & Wu, L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.018 · Cited by 122
Glycolysis-induced drug resistance in tumors—A response to danger signals?
Marcucci, F., & Rumio, C. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.009 · Cited by 122
Niche-Selective Inhibition of Pathogenic Th17 Cells by Targeting Metabolic Redundancy
Wu, L., Hollinshead, K. E. R., Hao, Y., Au, C., Kroehling, L., Ng, C., Lin, W.-Y., Li, D., Silva, H. M., Shin, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.014 · Cited by 119
Cappello, P., Tomaino, B., Chiarle, R., Ceruti, P., Novarino, A., Castagnoli, C., Migliorini, P., Perconti, G., Giallongo, A., Milella, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24355 · Cited by 116
Proteomics‐based identification of α‐enolase as a tumor antigen in non‐small lung cancer
He, P., Naka, T., Serada, S., Fujimoto, M., Tanaka, T., Hashimoto, S., Shima, Y., Yamadori, T., Suzuki, H., Hirashima, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00509.x · Cited by 114
Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
Shi, H., Li, D., Zhang, J., Wang, Y., Li, Y., Zhang, H., Wang, X., Mu, B., Wang, W., Ma, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01562.x · Cited by 114
Xintaropoulou, C., Ward, C., Wise, A., Queckbörner, S., Turnbull, A., Michie, C. O., Williams, A. R. W., Rye, T., Gourley, C., & Langdon, S. P. (2018) · BMC Cancer · doi:10.1186/s12885-018-4521-4 · Cited by 114
Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
Nakano, A., Tsuji, D., Miki, H., Cui, Q., Sayed, S. M. E., Ikegame, A., Oda, A., Amou, H., Nakamura, S., Harada, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027222 · Cited by 112
Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer
Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.020 · Cited by 110
Fiorillo, M., Ózsvári, B., Sotgia, F., & Lisanti, M. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740720 · Cited by 109
Targeting lactate transport suppressesin vivobreast tumour growth
Morais-Santos, F., Granja, S., Miranda‐Gonçalves, V., Moreira, A. H. J., Queirós, S., Vilaça, J. L., Schmitt, F. C., Longatto‐Filho, A., Paredes, J., Baltazar, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3910 · Cited by 107
Hagiya, Y., Fukuhara, H., Matsumoto, K., Endo, Y., Nakajima, M., Tanaka, T., Okura, I., Kurabayashi, A., Furihata, M., Inoue, K., et al. (2013) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2013.02.001 · Cited by 107
Huang, K., Liang, Q., Zhou, Y., Jiang, L.-L., Gu, W.-M., Luo, M., Tang, Y., Wang, Y., Lü, W., Huang, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.014 · Cited by 105
Xia, Q., Jia, J., Hu, C., Lu, J., Li, J., Xu, H., Fang, J., Feng, D., Wang, L., & Chen, Y. (2021) · Oncogene · doi:10.1038/s41388-021-02133-5 · Cited by 105
Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling
Atif, F., Yousuf, S., & Stein, D. G. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.04.007 · Cited by 104
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00313-3 · Cited by 100
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Guo, W., Zhang, Y., Chen, T., Wang, Y., Xue, J., Zhang, Y., Xiao, W., Mo, X., & Lü, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0860-5 · Cited by 99
Mohammad, G. H., Damink, S. W. M. O., Malagó, M., Dhar, D. K., & Pereira, S. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151635 · Cited by 99
The effect of 5-aminolevulinic acid on cytochrome c oxidase activity in mouse liver
Ogura, S., Maruyama, K., Hagiya, Y., Sugiyama, Y., Tsuchiya, K., Takahashi, K., Abe, F., Tabata, K., Okura, I., Nakajima, M., et al. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-66 · Cited by 98
Bacci, M., Giannoni, E., Fearns, A., Ribas, R., Gao, Q., Taddei, M. L., Pintus, G., Dowsett, M., Isacke, C. M., Martin, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2038 · Cited by 98
Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target
Almaguel, F. A., Sanchez, T. W., Ortiz-Hernández, G. L., & Casiano, C. A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.614726 · Cited by 97
Sato‐Tadano, A., Suzuki, T., Amari, M., Takagi, K., Miki, Y., Tamaki, K., Watanabe, M., Ishida, T., Sasano, H., & Ohuchi, N. (2013) · Cancer Science · doi:10.1111/cas.12238 · Cited by 96
Tilekar, K. N., Upadhyay, N., Iancu, C. V., Pokrovsky, V. S., Choe, J., & Ramaa, C. S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188457 · Cited by 95
Ganapathy‐Kanniappan, S., Kunjithapatham, R., & Geschwind, J.-F. H. (2012) · Oncotarget · doi:10.18632/oncotarget.623 · Cited by 94
Wang, J., Xu, W., Wang, B., Lin, G., Yu, W., Abudurexiti, M., Zhu, W., Liu, C., Qin, X., Dai, B., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.007 · Cited by 94
Yu, Y., Liang, Y., Li, D., Wang, L., Liang, Z., Chen, Y., Ma, G., Wu, H. M., Jiao, W., & Niu, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00401-7 · Cited by 94
Chen, Z., Wang, Y.-Z., Warden, C., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.02.004 · Cited by 93
Alpha-Enolase i ENO1 i a potential target in novel immunotherapies
Novelli, F. (2016) · Frontiers in bioscience · doi:10.2741/4526 · Cited by 93
Mori, Y., Yamawaki, K., Ishiguro, T., Yoshihara, K., Ueda, H., Sato, A., Ohata, H., Yoshida, Y., Minamino, T., Okamoto, K., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.08.015 · Cited by 91
Defueling the cancer: ATP synthase as an emerging target in cancer therapy
Wang, T., Ma, F., & Qian, H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.015 · Cited by 91
McNicholas, K., MacGregor, M., & Gleadle, J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0516-4 · Cited by 89
Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
Kwon, Y., Kim, M.-S., Jung, H. S., Kim, Y., & Jeoung, D. (2019) · Cancers · doi:10.3390/cancers11091374 · Cited by 89
The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism
Meng, Y., Xu, X. J., Luan, H., Li, L., Dai, W., Li, Z., & Bian, J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0052 · Cited by 89
Yoo, B. C., Ku, J., Hong, S., Shin, Y., Park, S. Y., Kim, H. K., & Park, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11604 · Cited by 87
Self-citationGlycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer
Rivenzon‐Segal, D., Boldin‐Adamsky, S., Seger, D., Seger, R., & Degani, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11387 · Cited by 86
Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair
Sizemore, S. T., Zhang, M., Cho, J. H., Sizemore, G. M., Hurwitz, B. S., Kaur, B., Lehman, N. L., Ostrowski, M. C., Robe, P. A. J. T., Miao, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0086-7 · Cited by 86
A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy
Luo, Y., Li, Y., Huang, Z., Li, X., Wang, Y., Hou, J., & Zhou, S. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c02475 · Cited by 86
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Keoh, L. Q., Chiu, C.-F., & Ramasamy, T. S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10956-y · Cited by 66
The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Aati, S., Farouk, H. O., Elkarmalawy, M. H., Aati, H. Y., Tolba, N. S., Hassan, H. M., Rateb, M. E., & Hamad, D. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111432 · Cited by 9
Metadata
- Authors
- Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-30
- Volume
- 24
- Issue
- 3
- Pages
- 2606
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4318478298
- Cited by
- 374
- References
- 316
- FWCI
- 36.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.